Compugen reported progress in its cancer immunotherapy programs, including active patient enrollment in the COM701 MAIA-ovarian trial with an interim analysis expected by Q1 2027. Partner AstraZeneca is advancing rilvegostomig through 11 Phase 3 trials, while the Gilead-partnered GS-0321 Phase 1 trial is progressing as planned. The company holds a solid financial position with approximately $135 million in cash and expects funding to last into 2029, supporting continued development of its AI-powered drug discovery platform and immuno-oncology pipeline.
The myasthenia gravis market, valued at around $6 billion in 2025, is projected to grow at a 9.1% CAGR to surpass $16 billion by 2036. Growth is fueled by increasing diagnosed cases, especially among older populations, and a surge in innovative targe...
AstraZeneca has received US approval for Baxfendy, the first new blood pressure drug class in over 20 years, which effectively lowers high blood pressure by blocking aldosterone production. This drug addresses a significant need as many patients stru...
